Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT01613040
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Rituximab
- First Posted Date
- 2012-06-06
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT01613027
A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01612143
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT01610791
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT01609543
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1496
- Registration Number
- NCT01609049
- Locations
- 🇷🇺
Kirov Region Aids-Center; Infectious, Kirov, Russian Federation
🇷🇺Infections Deseases Hospital #1, Novosibirsk, Russian Federation
🇷🇺Krasnoyarsk Region Aids Center; Hepatology, Krasnoyarsk, Russian Federation
A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT01609023
- Locations
- 🇬🇷
Metropolitan Hospital; Hematology Dept, Athens, Greece
🇬🇷University Hospital of Larissa; Hematology Dept., Larissa, Greece
🇬🇷Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens, Greece
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
- Conditions
- Colorectal Cancer
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 437
- Registration Number
- NCT01609075
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT01609010
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
- Conditions
- Lymphoma, Follicular
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01609036